Rheumatoid arthritis (RA) is a chronic autoimmune arthritis that affects approximately 1% of the population. Synovial inflammation cannot fully explain the level of pain reported by patients and facilitation of pain processing at the spinal level has been implicated. We characterized the K/BxN serum transfer arthritis model as a model of joint inflammation-induced pain and examined pharmacologic responsiveness and spinal glia activation. Mechanical allodynia developed congruently with joint swelling. Surprisingly, allodynia persisted after resolution of inflammation. At the peak of joint inflammation (days 4-10), hypersensitivity was attenuated with i.p. etanercept, gabapentin, and ketorolac. Following resolution of synovial inflammation (days 19-23), only gabapentin relieved allodynia. The superficial dorsal horn of arthritic mice displayed increased staining of microglia at early and late time points, but astrocyte staining increased only during the inflammatory phase. ATF3, a marker of nerve injury, was significantly increased in the lumbar dorsal root ganglia during the late phase (day 28). Hence, serum transfer in the K/BxN serum transfer arthritis model produces a persistent pain state, where the allodynia during the inflammatory state is attenuated by TNF and prostaglandin inhibitors, and the pharmacology and histochemistry data suggest a transition from an inflammatory state to a state that resembles a neuropathic condition over time. Therefore, the K/BxN serum transfer model represents a multifaceted model for studies exploring pain mechanisms in conditions of joint inflammation and may serve as a platform for exploring novel treatment strategies for pain in human arthritic conditions. Ó
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease hallmarked by synovial inflammation and matrix destruction. Therapy reduces clinical signs of arthritis, yet joint pain often persists [52] . Common rodent models used to study inflammation-induced pain include intra-plantar and intra-articular injections of inflammatory agents. Although useful, these models often do not fully address the impact of autoimmune mechanisms, such as B and T cell responses, nor do they allow the assessment of chronic inflammation. From this aspect, the K/BxN serum transfer model may be useful as a model of arthritis-induced pain.
K/BxN mice spontaneously produce autoantibodies against the ubiquitous protein glucose-6-phosphate isomerase (GPI), which is present in the joints, with the resultant immune complex-mediated development of inflammatory arthritis [33, 39] . Serum from these mice can be used to induce transient inflammatory arthritis in a wide range of mouse strains [42] . This broad transfer applicability distinguishes the K/BxN serum transfer model from many other common models of RA, such as collagen-induced arthritis (CIA), which requires a specific genetic background [9, 25] . The K/ BxN serum transfer model has a predictable onset of the clinical signs of arthritis as the recipient mice receive the same quantity of autoantibodies at the time of injection, and this model is not dependent upon breaking T cell tolerance. The clinical profile has a severe inflammatory phase that reliably resolves as the autoantibodies are cleared and not replenished by autologous B cells.
While well established in the RA field, the K/BxN serum transfer arthritis model has not been characterized as an experimental model of inflammatory pain. In humans and animal models, persistent inflammation in the joint is associated with ongoing pain and a hypersensitivity to innocuous stimuli [34, 49] . As ligaments, fibrous capsule, meniscus, periosteum and synovial layer are innervated by sensory Ab-, Ad-and C-fibers noxious sensation can be evoked from these structures [49] . The increased pain sensitivity
